New drug combo aims to shrink Hard-to-Treat head and neck tumors
NCT ID NCT06332092
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests two different doses of a nano-encapsulated chemotherapy drug called FID-007, combined with cetuximab, in 46 people with advanced head and neck cancer that has returned or spread. The goal is to see how well the combination shrinks tumors and to check for side effects. Participants must have already tried an immunotherapy drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FID-007 (a nano-encapsulated form of the chemotherapy drug paclitaxel) combined with cetuximab
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced head and neck cancer that has stopped responding to other therapies.
- What could go wrong
- This is a small, early-phase trial with only 46 participants. The combination may not work better than existing treatments, and side effects from chemotherapy and cetuximab are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46804, United States
-
Highlands Oncology - North Hills
Fayetteville, Arkansas, 72703, United States
-
Moffitt Cancer Center Magnolia Campus
Tampa, Florida, 33612, United States
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Texas Oncology - Northeast Texas Cancer & Research Institute
Tyler, Texas, 75702, United States
-
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?